949 related articles for article (PubMed ID: 34379821)
1. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.
Hunjan MK; Roberts C; Karim S; Hague J
Clin Exp Dermatol; 2022 Jan; 47(1):188-190. PubMed ID: 34379821
[TBL] [Abstract][Full Text] [Related]
2. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine.
Sechi A; Pierobon E; Pezzolo E; Germi L; Trevisan G; Zardo D; Riva G; Mondino S; Naldi L
Clin Exp Dermatol; 2022 Feb; 47(2):437-440. PubMed ID: 34617317
[No Abstract] [Full Text] [Related]
3. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
Jack A; Mauro MJ; Ehst BD
J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
[No Abstract] [Full Text] [Related]
4. Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu's arteritis.
Salman A; Sonmez Y; Sahin H; Unal AU; Direskeneli H; Cinel L; Ergun T
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 27862745
[No Abstract] [Full Text] [Related]
5. Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
Cheung EJ; Jedrych JJ; English JC
J Drugs Dermatol; 2015 Oct; 14(10):1161-2. PubMed ID: 26461830
[TBL] [Abstract][Full Text] [Related]
6. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
[TBL] [Abstract][Full Text] [Related]
7. Pityriasis rubra pilaris-like reaction induced by imatinib.
Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
[TBL] [Abstract][Full Text] [Related]
8. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine.
Hlaca N; Zagar T; Kastelan M; Peternel S; Brajac I; Dujmovic-Hasanbegovic K; Prpic-Massari L
Dermatol Ther; 2022 Nov; 35(11):e15791. PubMed ID: 36029037
[No Abstract] [Full Text] [Related]
9. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
10. Pityriasis Rubra Pilaris After Moderna COVID-19 Vaccination: A Case Report and Literature Review.
Liu YA; Dai J; Nagarajan P; Torres-Cabala CA; Aung PP; Prieto VG; Cho WC
Am J Dermatopathol; 2023 Mar; 45(3):185-188. PubMed ID: 36626570
[TBL] [Abstract][Full Text] [Related]
11. [Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?].
Bramhoff AC; Wesselmann U; Bender ST; Berghoff AV; Hofmann SC; Balakirski G
Dermatologie (Heidelb); 2022 Aug; 73(8):634-637. PubMed ID: 35296923
[TBL] [Abstract][Full Text] [Related]
12. Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac).
Fernández LT; Pérez-Garza DM; delaO-Escamilla A; Yamallel-Ortega LA; Cuellar-Barboza A; Ocampo-Candiani J; Chavez-Alvarez S
Dermatol Ther; 2022 Jun; 35(6):e15455. PubMed ID: 35297142
[No Abstract] [Full Text] [Related]
13. Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines.
Mohamed M; Belhadjali H; Hammedi F; Ben Meriem C; Zili J
Indian J Dermatol Venereol Leprol; 2015; 81(6):618-20. PubMed ID: 26515846
[No Abstract] [Full Text] [Related]
14. Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
Polat M; Lenk N; Ustün H; Oztaş P; Artüz F; Alli N
Pediatr Dermatol; 2007; 24(2):151-4. PubMed ID: 17461814
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
Paz C; Querfeld C; Shea CR
J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
[No Abstract] [Full Text] [Related]
16. Drugs associated with development of pityriasis rubra pilaris: A systematic review.
Mufti A; Lytvyn Y; Maliyar K; Sachdeva M; Yeung J
J Am Acad Dermatol; 2021 Apr; 84(4):1071-1081. PubMed ID: 32687965
[No Abstract] [Full Text] [Related]
17. [Telaprevir-induced pityriasis rubra pilaris].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
[No Abstract] [Full Text] [Related]
18. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.
Kreuter A; Licciardi-Fernandez MJ; Burmann SN; Burkert B; Oellig F; Michalowitz AL
Clin Exp Dermatol; 2022 Jan; 47(1):161-163. PubMed ID: 34291477
[TBL] [Abstract][Full Text] [Related]
19. [Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream].
Gómez-Moyano E; Crespo-Erchiga A; Vera Casaño A; Sanz Trelles A
Actas Dermosifiliogr; 2010 Dec; 101(10):898-900. PubMed ID: 21159271
[No Abstract] [Full Text] [Related]
20. Comment on 'Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine'.
Potestio L; Genco L; Noto M; Fabbrocini G; Battista T; Martora F
Clin Exp Dermatol; 2023 Jan; 48(1):44-45. PubMed ID: 36669180
[No Abstract] [Full Text] [Related]
[Next] [New Search]
